108 Participants Needed

Antibiotics Impact on Healthy Subjects

Recruiting at 1 trial location
LN
JD
JD
CS
LW
CD
Overseen ByCarla D Williams, R.N.
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

More than 250 million courses of antibiotics are prescribed annually in the ambulatory care setting in the United States alone, including more than 40 million in children under 18 years of age. The perception that antibiotic use has minimal attendant adverse side effects contributes to the over-utilization of antibiotics in clinical circumstances when they are not strictly indicated. We have learned much about the human microbiome. The emerging view is of profound life-long bi-directional interactions between our microbiota and our cells. Perturbations in the microbiota affect metabolic, immune, and cognitive physiology in experimental animal models. When a person takes an antibiotic, the antibiotic diffuses via the blood into all body compartments, selecting for resistance. We propose to examine the effects of two commonly used antibiotics (the beta-lactam, amoxicillin and the macrolide azithromycin) on human microbial populations and on metabolic and immune physiology, studying healthy human volunteers in a randomized controlled clinical trial at the NIH Clinical Center. Our hypothesis is that in addition to acutely perturbing the human microbiome, these agents will have measurable metabolic and immunologic effects, with residual effects in the weeks that follow. To test this hypothesis, we will assess the effects of a brief therapeutic course of antibiotics on microbiome and metagenome composition. After an initial evaluation period, antibiotics will be given for 7 days or 5 days (depending on the antibiotic), and there will be a post-treatment evaluation. A control group will receive no drug intervention. Specimens will be obtained from multiple sites at each of 10 time points occurring before, during, and after antibiotic administration, and used for estimating bacterial and fungal composition and gene content. We will also assess the effects of the antibiotic course on markers of innate and adaptive immunity as well as markers of metabolic and hormonal physiology. A subgroup of subjects will be studied in the clinical center metabolic chamber to assess 24-hour energy expenditure and its components (sleeping, diet-induced, and activity energy expenditure), as well as macronutrient oxidation rates (carbohydrate, fat, and protein), during 3 of the 10 study visits. In addition to the primary data analyses, we will build a model that integrates the temporal data to begin to understand the complex intertwined physiology between microbiome and host.

Will I have to stop taking my current medications?

The trial requires that participants have not used certain medications, like antibiotics, antifungals, antivirals, corticosteroids, and others, within the last 6 months. If you are currently taking any of these, you would need to stop and wait for the specified period before joining the trial.

What data supports the effectiveness of the drug amoxicillin and azithromycin?

Research shows that azithromycin is highly effective in treating lower respiratory infections, with a success rate of over 93% in some cases. Additionally, both amoxicillin and azithromycin have been effective in treating ear, nose, and throat infections, as well as preventing recurrent ear infections.12345

Is it safe for healthy people to take antibiotics like Amoxicillin and Azithromycin?

Antibiotics like Amoxicillin and Azithromycin are generally considered safe, but they can cause side effects such as stomach upset and, in rare cases, more serious issues like allergic reactions or gait disturbances. Most side effects are mild and temporary, but it's important to monitor for any unusual symptoms.678910

How does the drug Amoxicillin and Azithromycin differ from other treatments?

Amoxicillin and Azithromycin are antibiotics that may have unique effects on weight gain, as seen in studies where Amoxicillin promoted short-term weight gain in children. Azithromycin is well-tolerated with fewer side effects compared to other antibiotics, but it has been linked to an increased risk of cardiovascular death in some cases.1112131415

Research Team

CS

Christa S Zerbe, M.D.

Principal Investigator

National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility Criteria

Healthy adults aged 18-50 who can swallow capsules and comply with study procedures. Participants must be willing to allow storage of their biological samples but cannot have used certain medications or substances in the past months, including systemic antibiotics, steroids, probiotics, antacids, laxatives, and more. Smokers and those with a range of health conditions or recent significant weight changes are excluded.

Inclusion Criteria

I am between 18 and 50, healthy, and okay with giving samples and taking capsules for a study.

Exclusion Criteria

I have certain skin conditions.
I cannot attend all the required study visits.
Any condition contraindicating study participation
See 23 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either amoxicillin for 7 days or azithromycin for 5 days, with a control group receiving no drug intervention

1 week
10 visits (in-person)

Post-treatment Evaluation

Participants are evaluated for changes in microbiome, immune, and metabolic parameters after antibiotic administration

2-4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Amoxicillin
  • Azithromycin
  • Control
Trial OverviewThe MIME Study is testing how two common antibiotics—amoxicillin and azithromycin—affect the human microbiome as well as metabolic and immune physiology in healthy volunteers. It's a randomized controlled trial where one group receives amoxicillin for 7 days, another azithromycin for 5 days, while a control group gets no drug intervention.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Group CExperimental Treatment1 Intervention
Azithromycin
Group II: Group BExperimental Treatment1 Intervention
Amoxicillin
Group III: Group AExperimental Treatment1 Intervention
Control

Amoxicillin is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Amoxicillin for:
  • Bacterial infections
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and soft tissue infections
  • Ear, nose and throat infections
🇺🇸
Approved in United States as Amoxicillin for:
  • Infections of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract
🇨🇦
Approved in Canada as Amoxicillin for:
  • Bacterial infections
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and soft tissue infections

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Institute of Allergy and Infectious Diseases (NIAID)

Lead Sponsor

Trials
3,361
Recruited
5,516,000+

Findings from Research

In a study analyzing 102 medical files, 71% of amoxicillin-clavulanic acid prescriptions were found to be appropriate according to hospital guidelines, indicating a generally good adherence to antibiotic prescribing standards.
However, 15% of prescriptions were deemed unacceptable, often made by junior doctors, highlighting the need for improved training and oversight to optimize antibiotic use, especially for acute pulmonary infections.
[Evaluation of amoxicillin-clavulanic acid prescriptions in a teaching hospital of Parisian suburb].Dupont, C., Massé, C., Auvert, B., et al.[2019]
In a study of 71 children with recurrent acute otitis media, both azithromycin and amoxicillin were found to be effective in reducing the number of AOM episodes, with clinical response rates of 80.6% and 89.5%, respectively.
The safety profiles of both treatments were similar, indicating that azithromycin can be considered a viable alternative to amoxicillin for preventing recurrent AOM.
Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media.De Diego, JI., Prim, MP., Alfonso, C., et al.[2019]
In a study of 153 patients with lower respiratory tract infections, azithromycin demonstrated high clinical effectiveness, achieving a 93.6% success rate in treating community-acquired pneumonia (CAP) and 94.9% in acute exacerbation of chronic bronchitis (AECB).
Azithromycin provided symptom relief within three days for 88.6% of CAP patients and 77.2% of AECB patients, with only a small incidence of adverse events (9.1%), primarily gastrointestinal issues like abdominal pain and diarrhea.
SAFETY AND EFFECTIVENESS OF AZITHROMYCIN IN THE TREATMENT OF LOWER RESPIRATORY INFECTIONS: AN INTERNATIONAL, MULTICENTER, NON-COMPARATIVE STUDY.Gašparić, M., Penezić, A., Kolumbić-Lakoš, A., et al.[2018]

References

[Evaluation of amoxicillin-clavulanic acid prescriptions in a teaching hospital of Parisian suburb]. [2019]
Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media. [2019]
SAFETY AND EFFECTIVENESS OF AZITHROMYCIN IN THE TREATMENT OF LOWER RESPIRATORY INFECTIONS: AN INTERNATIONAL, MULTICENTER, NON-COMPARATIVE STUDY. [2018]
Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. [2019]
A multicenter study on the clinical efficacy and safety of roxithromycin in the treatment of ear-nose-throat infections: comparison with amoxycillin/clavulanic acid. [2013]
Potential safety signals for antibacterial agents from the Brazilian national pharmacovigilance database (Vigimed/VigiFlow). [2022]
The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections. [2022]
Pharmacovigilance Data as a Trigger to Identify Antimicrobial Resistance and Inappropriate Use of Antibiotics: A Study Using Reports from The Netherlands Pharmacovigilance Centre. [2021]
Safety of antibiotic drugs in food animals: comparison of findings from preapproval studies and postapproval experience in the United States with safety information in published literature. [2013]
10.United Arab Emiratespubmed.ncbi.nlm.nih.gov
Separating fact from fiction: the data behind allergies and side effects caused by penicillins, cephalosporins, and carbapenem antibiotics. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
Association of Azithromycin Use With Cardiovascular Mortality. [2021]
12.United Statespubmed.ncbi.nlm.nih.gov
Clinical toleration and safety of azithromycin. [2022]
Effect of long-term antibiotic use on weight in adolescents with acne. [2018]
14.United Statespubmed.ncbi.nlm.nih.gov
Effect of Antibiotics on Short-Term Growth among Children in Burkina Faso: A Randomized Trial. [2022]
A Phase I Determination of Azithromycin in Plasma during a 6-Week Period in Normal Volunteers after a Standard Dose of 500mg Once Daily for 3 Days. [2021]